![Eric Schlumpf](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Positionen von Eric Schlumpf
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Stuart Therapeutics LLC
![]() Stuart Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Stuart Therapeutics LLC, founded in 2017, is a company based in Stuart, FL that specializes in the development of ECM-targeting therapeutics for disease treatment. Stuart Therapeutics has conducted extensive research in a variety of anterior and posterior segment ophthalmic disease indications, demonstrating rapid effects in treated tissues. The company's patented platform technology, PolyCol™, is a portfolio of synthesized collagen mimetic peptides designed to repair disease or injury-damaged helical collagen structures. This repair results in a restoration of homeostatic cell signaling, positively affecting cell growth and proliferation while reducing inflammation. The company was founded in 2018 by Eric Schlumpf, who has been the CEO since then. | Direktor/Vorstandsmitglied | 01.01.2018 | - |
Vorstandsvorsitzender | 01.01.2018 | - | |
Gründer | 01.01.2018 | - | |
Präsident | 01.01.2018 | - |
Karriereverlauf von Eric Schlumpf
Statistik
International
Vereinigte Staaten | 2 |
Operativ
Director/Board Member | 1 |
Chief Executive Officer | 1 |
Founder | 1 |
Sektoral
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Stuart Therapeutics LLC
![]() Stuart Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Stuart Therapeutics LLC, founded in 2017, is a company based in Stuart, FL that specializes in the development of ECM-targeting therapeutics for disease treatment. Stuart Therapeutics has conducted extensive research in a variety of anterior and posterior segment ophthalmic disease indications, demonstrating rapid effects in treated tissues. The company's patented platform technology, PolyCol™, is a portfolio of synthesized collagen mimetic peptides designed to repair disease or injury-damaged helical collagen structures. This repair results in a restoration of homeostatic cell signaling, positively affecting cell growth and proliferation while reducing inflammation. The company was founded in 2018 by Eric Schlumpf, who has been the CEO since then. | Commercial Services |
- Börse
- Insiders
- Eric Schlumpf
- Erfahrung